Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review
Introduction and purpose: Over the past two decades, the management of severe asthma shifted from high doses of inhaled and oral corticosteroids to targeted biologic agents. Adverse effects of treatment with monoclonal antibodies are not yet fully characterised. The aim of this paper is to provide a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2024-11-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/55855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221293892698112 |
|---|---|
| author | Izabela Orzołek Izabela Stawicka Jakub Jarmołowicz Agata Boczar Patryk Dryja |
| author_facet | Izabela Orzołek Izabela Stawicka Jakub Jarmołowicz Agata Boczar Patryk Dryja |
| author_sort | Izabela Orzołek |
| collection | DOAJ |
| description | Introduction and purpose: Over the past two decades, the management of severe asthma shifted from high doses of inhaled and oral corticosteroids to targeted biologic agents. Adverse effects of treatment with monoclonal antibodies are not yet fully characterised. The aim of this paper is to provide a comprehensive review of the adverse effects of the FDA-approved monoclonal antibodies in the treatment of moderate-to-severe asthma, including omalizumab, benralizumab, dupilumab, mepolizumab, reslizumab, tezepelumab.
Material and methods of research: A thorough literature review was performed using PubMed Web of Science and Embase, employing key words related to monoclonal antibodies, asthma and adverse effects.
Description of the state of knowledge: Omalizumab and mepolizumab have black box warning on the risk of anaphylaxis. Due to scarcity of data, no causal association between the use of monoclonal antibodies and risk of malignancy can be established. The most common adverse effects of biologic agents in severe asthma include upper respiratory tract infections, nasopharyngitis and asthma worsening.
Conclusions: Overall, monoclonal antibodies have a favourable safety profile, with certain risk of side effects remains present, and is variable for the different molecules. More studies of asthmatic patients treated with monoclonal antibodies are needed to spot rare adverse events and those developing over longer time.
|
| format | Article |
| id | doaj-art-ab9f11fcadee4604a06f6767076d3c78 |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-ab9f11fcadee4604a06f6767076d3c782024-11-17T08:01:38ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062024-11-017010.12775/JEHS.2024.70.55855Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative reviewIzabela Orzołek0Izabela Stawicka1Jakub Jarmołowicz2Agata Boczar3Patryk Dryja4Czerniakowski Hospital, Stępińska 19/25, 00-739 Warsaw, PolandCental Clinical Hospital, Medical University of Warsaw, Stefana Banacha 1a, 02-097, Warsaw, Wrocław University Hospital, Borowska 213, 50-556 WrocławWrocław University Hospital, Borowska 213, 50-556 WrocławOpole University Hospital al. W.Witosa 26 45-401 OpoleIntroduction and purpose: Over the past two decades, the management of severe asthma shifted from high doses of inhaled and oral corticosteroids to targeted biologic agents. Adverse effects of treatment with monoclonal antibodies are not yet fully characterised. The aim of this paper is to provide a comprehensive review of the adverse effects of the FDA-approved monoclonal antibodies in the treatment of moderate-to-severe asthma, including omalizumab, benralizumab, dupilumab, mepolizumab, reslizumab, tezepelumab. Material and methods of research: A thorough literature review was performed using PubMed Web of Science and Embase, employing key words related to monoclonal antibodies, asthma and adverse effects. Description of the state of knowledge: Omalizumab and mepolizumab have black box warning on the risk of anaphylaxis. Due to scarcity of data, no causal association between the use of monoclonal antibodies and risk of malignancy can be established. The most common adverse effects of biologic agents in severe asthma include upper respiratory tract infections, nasopharyngitis and asthma worsening. Conclusions: Overall, monoclonal antibodies have a favourable safety profile, with certain risk of side effects remains present, and is variable for the different molecules. More studies of asthmatic patients treated with monoclonal antibodies are needed to spot rare adverse events and those developing over longer time. https://apcz.umk.pl/JEHS/article/view/55855monoclonal antibodiesasthmabiologicsadverse eventsallergy |
| spellingShingle | Izabela Orzołek Izabela Stawicka Jakub Jarmołowicz Agata Boczar Patryk Dryja Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review Journal of Education, Health and Sport monoclonal antibodies asthma biologics adverse events allergy |
| title | Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review |
| title_full | Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review |
| title_fullStr | Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review |
| title_full_unstemmed | Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review |
| title_short | Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review |
| title_sort | adverse effects of monoclonal antibodies in the treatment of moderate to severe asthma a narrative review |
| topic | monoclonal antibodies asthma biologics adverse events allergy |
| url | https://apcz.umk.pl/JEHS/article/view/55855 |
| work_keys_str_mv | AT izabelaorzołek adverseeffectsofmonoclonalantibodiesinthetreatmentofmoderatetosevereasthmaanarrativereview AT izabelastawicka adverseeffectsofmonoclonalantibodiesinthetreatmentofmoderatetosevereasthmaanarrativereview AT jakubjarmołowicz adverseeffectsofmonoclonalantibodiesinthetreatmentofmoderatetosevereasthmaanarrativereview AT agataboczar adverseeffectsofmonoclonalantibodiesinthetreatmentofmoderatetosevereasthmaanarrativereview AT patrykdryja adverseeffectsofmonoclonalantibodiesinthetreatmentofmoderatetosevereasthmaanarrativereview |